MBX Biosciences Inc’s recently made public that its President & CEO Hawryluk P. Kent acquired Company’s shares for reported $0.27 million on Oct 20 ’25. In the deal valued at $13.64 per share,20,000 shares were bought. As a result of this transaction, Hawryluk P. Kent now holds 468,277 shares worth roughly $15.45 million.
Then, Hoerter Steven L. bought 20,000 shares, generating $264,984 in total proceeds. Upon buying the shares at $13.25, the Director now owns 20,000 shares.
Before that, Heron Patrick J bought 666,666 shares. MBX Biosciences Inc shares valued at $11,999,988 were divested by the Director at a price of $18.00 per share. As a result of the transaction, Heron Patrick J now holds 5,219,440 shares, worth roughly $172.24 million.
TD Cowen initiated its MBX Biosciences Inc [MBX] rating to a Buy in a research note published recently. A number of analysts have revised their coverage, including Truist’s analysts, who began to cover the stock in mid October with a ‘”a Buy”‘ rating. Mizuho started covering the stock on August 05, 2025. It rated MBX as “an Outperform”.
Price Performance Review of MBX
On Monday, MBX Biosciences Inc [NASDAQ:MBX] saw its stock fall -4.32% to $33.0. Over the last five days, the stock has gained 21.86%. MBX Biosciences Inc shares have risen nearly 66.41% since the year began. Nevertheless, the stocks have risen 79.06% over the past one year. While a 52-week high of $34.83 was reached on 11/28/25, a 52-week low of $4.81 was recorded on 04/07/25.
Levels Of Support And Resistance For MBX Stock
The 24-hour chart illustrates a support level at 32.37, which if violated will result in even more drops to 31.75. On the upside, there is a resistance level at 34.10. A further resistance level may holdings at 35.21.
How much short interest is there in MBX Biosciences Inc?
A steep rise in short interest was recorded in MBX Biosciences Inc stocks on 2025-11-14, growing by 0.72 million shares to a total of 4.63 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 3.91 million shares. There was a rise of 15.55%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 16, 2025 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $38 price target.
